The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updates to CORE-008: A phase 2 multi-arm, multi-cohort study to evaluate intravesical cretostimogene grenadenorepvec in patients with high-risk non-muscle invasive bladder cancer.
 
Gary Steinberg
Stock and Other Ownership Interests - CG Oncology; enGene; Epivax Therapeutics
Honoraria - Aduro Biotech; AstraZeneca; Bristol-Myers Squibb; CG Oncology; enGene; Epivax Oncology; fergene; Ferring; Fidia Farmaceutici S. p. A.; FKD Therapies; Janssen Oncology; MDxHealth; Merck; Pfizer; Photocure; Roche/Genentech; Seagen; Sesen Bio; Urogen pharma
Consulting or Advisory Role - Asieris Pharmaceuticals; AstraZeneca; Aura Biosciences; Boston Scientific; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; Imvax; MDxHealth; Merck; NanOlogy; Natera; Nonagen Bioscience; photocure; Roche/Genentech; Taris BioMedical; Verity Pharmaceuticals
 
Trinity Bivalacqua
Consulting or Advisory Role - CG Oncology; Ferring; UroGen pharma
Travel, Accommodations, Expenses - CG Oncology
 
Siamak Daneshmand
Stock and Other Ownership Interests - Taris
Honoraria - Allergan (I); AstraZeneca; Bausch and Lomb (I); Bristol-Myers Squibb; CG Oncology; enGene; Ferring; ImmunityBio; Johnson & Johnson; pacific edge; Pfizer; Photocure; Protara Therapeutics; Sesen Bio; Storz; Urogen pharma
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb/Pfizer; CG Oncology; enGene; Ferring; ImmunityBio; Johnson & Johnson/Janssen; pacific edge; Pfizer; Photocure; Taris; Urogen pharma; UroToday
Research Funding - Photocure
Travel, Accommodations, Expenses - Janssen Oncology; Photocure
 
Neal Shore
Employment - GenesisCare
Consulting or Advisory Role - Accord Research; Alessa Therapeutics; Amgen; Antev; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; Ferring; Fize Medical; Glytherix; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Peerview; Pfizer; Photocure; PlatformQ Health; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Siemens; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Tutelix; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
 
Shreyas Joshi
No Relationships to Disclose
 
Colin Dinney
Stock and Other Ownership Interests - CG Oncology
Consulting or Advisory Role - CG Oncology
Research Funding - CG Oncology
Patents, Royalties, Other Intellectual Property - Ferring